 |
More: 15th Conference on Retroviruses and Opportunistic Infections (CROI) CROI 2008: Challenges in Antiretroviral Therapy: Complications, Pharmacology, and Resistance Issues CME February 3 - 6, 2008, Boston, Massachusetts Author Information and Disclosures This activity is not sanctioned by, nor a part of, the 15th Conference on Retroviruses and Opportunistic Infections.
Release Date: February 29, 2008; Valid for credit through March 1, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 15th Conference on Retroviruses and Opportunistic Infections. These materials and the related activity are not sanctioned by the 15th Conference on Retroviruses and Opportunistic Infections or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review current HIV management guidelines for treatment-naive patients
- Update clinical practice by incorporating novel treatment data presented at CROI
- Discuss the most effective means of assessing risk and preventing and
managing metabolic comorbidities associated with HIV and antiretroviral therapy
Authors and Disclosures Ian Sanne, MD
Disclosure: Ian Sanne, MD, has disclosed that he has served as an advisor to Bristol-Myers Squibb. David M. Burger, PharmD, PhD
Disclosure: David M. Burger, PharmD,
PhD, has disclosed that he has received grants for clinical research from Gilead, Bristol-Myers Squibb, Abbott, Merck, Roche, and GlaxoSmithKline. Dr. Burger has also disclosed that he has received grants for educational activities from Gilead, Bristol-Myers Squibb, and Boehringer Ingelheim. Dr. Burger has also disclosed that he has served as an advisor or consultant to Bristol-Myers Squibb, Abbott, Merck, Roche, GlaxoSmithKline, and Tibotec.
William A. O'Brien, MD
Disclosure: William A. O'Brien, MD, has disclosed that he has received grants for clinical research from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Panacos, Schering, and Tibotec. Dr. O'Brien has also disclosed that he has served as an advisor or consultant to Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Tibotec, Virco, Siemens/Bayer, and Gilead.
Thomas Maxwell Mundy, MD
Disclosure: Thomas Maxwell Mundy, MD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
